Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-2 pulsed DC1 vaccine + trastuzumab in DCIS
NCT02336984Phase 2Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2014
- Primary completion
- Apr 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of her2 peptide-pulsed dendritic cells in ductal carcinoma in situ (DCIS), sponsored by Moffitt Cancer Center. Primary endpoint: Occurrence of Related Adverse Events at 5 years. Planned start Jun 2014; status: withdrawn.
02
Drugs
her2 peptide-pulsed dendritic cells
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT02336984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336984.